News
HOME > News
Taiwan’s FDA-approved Antrodia cinnamomea products are now ready to see the world
2021-04-27
Unique Satellite TV News

Good news from Taiwan’s biotechnology industry!

A Taiwan biotechnology company focusing on the research and development of Antrodia cinnamomea mycelia an ingredient used in dietary supplements, made it to the FDA’s new dietary ingredients list earlier this year and can now be sold in the United States, making it the first A. cinnamomea R&D company in Taiwan whose product can be seen on the NDI list. The FDA’s decision is a milestone for Taiwan’s A. cinnamomea products and lets the world see Taiwan’s A. cinnamomea industry, paving the way for the industry to enter the multibillion-dollar dietary supplement market in the United States.

After completing several thousand tests of culture medium combinations that stimulated different growing environments for A. cinnamomea mycelia, the company announced that it received an acknowledgment letter without objection in response to its new dietary ingredients (NDI) notification for A. cinnamomea mycelia from the USFDA and can now be sold in the United States as a safe dietary ingredient. The company’s A. cinnamomea mycelia are the first A. cinnamomea product in the world to receive international reorganization and may help Taiwan’s A. cinnamomea industry make inroads into the multibillion-dollar dietary supplement market worldwide.

Lo Hsuan, the chief executive officer of the biotech company, said, “we were surprised when we received the notification, and we also noticed that there have been many companies trying to get their products acknowledged as an NDI. Though we are the first company to receive an acknowledgment letter without objection, we sincerely hope our counterparts can follow suit. I hope our achievement can inspire other players in the industry and bring A. cinnamomea on the world stage.”  

According to the biotech company, in the Western world, applications of A. cinnamomea are scarce and its history less known, making it difficult to promote it as a dietary supplement ingredient or for medical use. The notification may help Taiwan’s A. cinnamomea industry make inroads into the multibillion-dollar dietary supplement market in the United States.

Hsiao, Chien-Fu, the chairperson of the Taiwan Niu-Chang-Chih (A. cinnamomea) Industry Association, said, “with scientific support, we hope the industry can fare better in the future and be seen by the world. Just like Korean ginseng, we hope A. cinnamomea can become our national treasure and be sold around the world.” 

With conservation and sustainability in mind, the biotech company’s team took great efforts to design a manufacturing process that uses a patented technology called solid-state fermentation. The company abandoned the traditional way that uses basswood to cultivate A. cinnamomea and applies the patented technology to produce A. cinnamomea mycelia, whose active ingredient content is similar with three years of A. cinnamomea fruiting body. The solid-state fermentation is able to reduce the cost and time for producing A. cinnamomea.

Chen, Wei-Ren, the chairperson of the Taiwan Functional Food Industry Association, said, “when compared with other international players, Taiwan is very competitive when it comes to the technologies of preparation, condensing, and extraction. After Covid-19, I think the public is equipped with more know-how and knowledge about nutrition and health care. We are looking forward to a fast-growing market.” 
A myriad of A. cinnamomea R&D results accumulated throughout the years has brought several breakthroughs for dietary supplement and gives the public more options to choose from in the post-pandemic era. 




Source: Taiwan’s FDA-approved antrodia cinnamomea products are now ready to see the world
© 2015 Greenyn Biotechnology Co.,Ltd. All Rights Reserved │ WEB DESIGN BY MOONLIGHT